Non-dilutive funding is any capital that does not require you to surrender equity, board seats, or decision-making power. For B2B SaaS founders, it is the fastest-growing segment of the capital market and the most misunderstood. This guide maps every major non-dilutive instrument available in Europe, breaks down the real costs, and helps you decide which one fits your stage and strategy.
Every SaaS founder eventually faces the same question: how do I fund the next phase of growth without handing over a slice of the company I built? In 2026, the answer is no longer "you can't." The non-dilutive funding market in Europe has matured significantly, and founders now have real options if they know where to look and what to watch out for.
This sounds straightforward, but in practice the line between "dilutive" and "non-dilutive" is blurrier than most founders realise.
Non-dilutive funding is capital that does not require you to issue new shares, grant warrants, or give up any ownership stake in your company. You receive money. You pay it back (or fulfil grant conditions). Your cap table stays exactly the way it was.
Several instruments market themselves as non-dilutive but carry hidden equity costs:
The rule of thumb: If any part of the agreement gives the capital provider the right to own shares in your company now or in the future it is not truly non-dilutive. Read the fine print.
The market for non-dilutive funding in Europe has expanded well beyond bank loans and government grants. Here are the major categories, ranked roughly by accessibility for a B2B SaaS company with €250K–€10M ARR.
Revenue-based financing is a broad category of instruments that underwrite against your recurring revenue — ARR, MRR trends, retention metrics — rather than requiring physical collateral or a profitable P&L. The category has evolved significantly, and today includes two distinct models:
You receive a lump sum and repay a fixed percentage of monthly revenue until you reach a repayment cap (typically 1.4–2x the original amount). Repayments fluctuate with revenue — good months cost more, slow months cost less.
Best for: Companies that want a single capital injection with repayments that flex with revenue. Suits businesses with variable monthly income that prefer lower payments during slower periods.
A newer model where you receive a credit line and draw capital as needed. Repayments are fixed and predictable, interest is fixed, and your credit limit grows with your ARR. This is how providers like Float structure their Growth Funding product: you draw, repay, and draw again, rather than taking a single lump sum.
Best for: SaaS companies that want ongoing, flexible access to capital — drawing incrementally for hiring, marketing, or expansion as opportunities arise, rather than committing to a single large draw. See what you can get.
European governments offer a broad range of non-dilutive funding through innovation grants, R&D incentives, and startup support programmes. These are genuinely free capital, no repayment, no equity, but they come with significant strings attached.
Best for: Companies with genuine R&D spend and the administrative bandwidth to manage compliance, reporting, and milestone obligations. Not suitable as your primary growth capital; the timelines are too slow and the amounts too unpredictable.
Traditional banks and specialist lenders have begun offering term loans structured around SaaS metrics rather than physical assets. These sit somewhere between a conventional bank facility and revenue-based financing.
Best for: Companies with strong financials that want a larger, longer-term facility and are willing to navigate traditional credit processes. Often requires personal guarantees or a debenture over company assets, check carefully.
Choosing between non-dilutive funding instruments requires weighing more than just the interest rate. Here is how the major options compare on the dimensions that actually matter to a SaaS operator.
A small but growing number of venture debt providers now offer facilities without warrant coverage. This makes the instrument genuinely non-dilutive, though it still comes with covenants, fees, and structural complexity.
Best for: Post-Series A companies that want a large lump sum and have the financial sophistication to manage covenant compliance. The "no warrant" versions are rarer and often reserved for stronger credits.
If your customers pay annually, you can unlock that cash upfront by selling or borrowing against those contracted future payments. Several fintech platforms now offer this for SaaS businesses.
Best for: Companies with a high proportion of annual contracts and a need for immediate cash. Less useful if your revenue is mostly monthly.
The original non-dilutive funding source: your own revenue. It costs nothing, requires no applications, and imposes no covenants. But it does impose a speed limit on growth.
Many bootstrapped founders assume the choice is binary: stay self-funded and grow slowly, or raise equity and give up control. A revolving credit facility like Float's Growth Funding offers a third path: access growth capital when you need it, repay it from revenue, and keep your cap table clean. You stay bootstrapped in every way that matters: no investors, no board seats, no dilution. You just remove the speed limit.
Best for: Capital-efficient founders who want to stay independent. If you're competing against well-funded rivals but don't want to raise equity, pairing retained earnings with a non-dilutive credit facility lets you move at venture speed without venture strings.
Non-dilutive funding is not universally superior to equity. It is a different tool with different strengths. Knowing when to reach for it, and when to raise a round instead is what separates strategic capital allocation from ideological stubbornness.
Founders often underestimate the true cost of equity because it does not show up on a monthly bank statement. But the maths is unforgiving.
Consider a founder who owns 60% of a company valued at €10M. A Series A round at 20% dilution drops that to 48%. A Series B at another 20% drops it to 38.4%. By Series C, the founder who started with full ownership may hold less than 30%.
Now imagine the same founder used non-dilutive funding to bridge from Seed to Series A, pushing the Series A valuation from €10M to €20M. Even with the same 20% dilution, they retain a larger share of a bigger pie, and they skipped an entire dilutive round.
This is not anti-VC rhetoric. It is arithmetic. The goal is not to avoid equity entirely but to use it only when you truly need what equity provides: risk capital, strategic partnership, and validation. Everything else the predictable, ROI-positive spend, should be funded with capital that does not cost you ownership.
No. Many debt instruments, particularly venture debt and convertible notes, include warrants, conversion rights, or equity kickers that create dilution. Always check whether the agreement includes any mechanism for the lender to acquire equity in your company. If it does, it is not non-dilutive.
Absolutely. The most capital-efficient SaaS operators use a layered approach: equity for high-risk, transformational investments; non-dilutive capital for predictable, ROI-positive spend like sales hiring and marketing. This "capital stack" strategy lowers your blended cost of capital and preserves equity for when it truly matters.
Requirements vary by instrument. Government grants require an eligible project and jurisdiction. Revenue-based financing typically requires a minimum ARR (Float's threshold is €250K), at least 12 months of revenue history, and a European or UK headquarters. Bank loans may require personal guarantees and a track record of profitability.
Float provides a revolving credit facility linked to your ARR. You connect your financial data via API, receive a credit offer within days, and draw down capital as needed. Terms range from 6–15 months with an optional grace period. Interest is fixed, there are no warrants, no personal guarantees, and no board seats. You only pay for what you use, and your credit limit grows as your revenue does.
Generally, no. Most non-dilutive instruments require some form of revenue or contracted income as the basis for underwriting. Pre-revenue companies are typically better served by grants, accelerator programmes, or early-stage equity. Once you have predictable recurring revenue, the full non-dilutive toolkit opens up.
